Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group

There are limited effective therapies for most patients with relapsed diffuse large B-cell lymphoma (DLBCL). We conducted a phase II trial of the multi-targeted vascular endothelial growth factor receptor (VEGFR) kinase inhibitor, sunitinib, 37.5 mg given orally once daily in adult patients with rel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Buckstein, Rena, Kuruvilla, John, Chua, Neil, Lee, Christina, Macdonald, David A, Al-Tourah, Abdulwahab J, Foo, Alison H, Walsh, Wendy, Ivy, S Percy, Crump, Michael, Eisenhauer, Elizabeth A
Formato: Artigo
Idioma:Inglês
Publicado em: Informa Healthcare 2011
Assuntos:
Original Article: Clinical
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3082168/
https://ncbi.nlm.nih.gov/pubmed/21463120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2011.555892
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados